Syncom Formulations (India) Limited reported a consolidated net profit of ₹2484.68 lakh for the quarter ended June 30, 2026, marking a 57.7% year-on-year increase from ₹1575.44 lakh in Q1FY26. The pharmaceutical manufacturer’s standalone net profit rose 56.3% to ₹2458.92 lakh, driven by improved operating leverage and significant expansion in EBITDA margins. This performance highlights strong profitability in its core drugs and formulations segment amidst moderate revenue growth.

The Board of Directors approved the unaudited financial results at a meeting held on August 11, 2026, in Indore. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors Sanjay Mehta & Associates, in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015. Chairman and Wholetime Director Ankit Kedarmal Bankda signed off on the filings, which were subsequently submitted to the BSE and NSE. The company also published the extract of results in the Free Press Journal on August 12, 2026.

Financial Performance Highlights

Standalone revenue from operations grew 6.9% YoY to ₹12465.95 lakh, up from ₹11654.69 lakh in Q1FY26. Total income stood at ₹13247.75 lakh, compared to ₹12256.66 lakh in the prior year period. On a consolidated basis, revenue from operations increased 7.3% YoY to ₹12552.64 lakh, while total income reached ₹13335.58 lakh. The consolidated EBITDA margin expanded significantly to 20.87% from 13.52% in the year-ago period, reflecting strong operating leverage and improved cost efficiency.

The following table summarises key financial metrics across both standalone and consolidated bases:

Profit before tax on a standalone basis was ₹3190.88 lakh, up from ₹2025.83 lakh in Q1FY26. Consolidated profit before tax rose to ₹3225.22 lakh from ₹2029.24 lakh. Tax expense remained stable at ₹731.96 lakh (standalone) and ₹740.54 lakh (consolidated), resulting in effective tax rates of approximately 22.9% for both bases.

Segment-Wise Breakdown

The Pharmaceuticals Drugs & Formulations segment contributed ₹13135.78 lakh (standalone) and ₹13223.61 lakh (consolidated) to total segment revenue, representing over 99% of income. This segment generated a pre-tax profit of ₹3134.50 lakh (standalone) and ₹3170.25 lakh (consolidated), demonstrating strong operational efficiency.

Trading of Commodities and Renting of Property contributed minimally, with combined revenues of ₹111.97 lakh (standalone) and ₹111.97 lakh (consolidated). Segment assets totaled ₹54761.88 lakh (standalone) and ₹55298.95 lakh (consolidated), reflecting continued investment in manufacturing infrastructure and property holdings.

What the Numbers Show

A key analytical observation is the divergence between revenue growth and expense management. While revenue grew nearly 7%, total expenses decreased slightly on a standalone basis from ₹10234.96 lakh to ₹10056.87 lakh, indicating improved cost control. This efficiency gain significantly amplified profit margins, with PBT margins expanding from 17.3% to 24.1%. Additionally, the company corrected its EPS calculation method to comply with Ind AS 33, restating comparative EPS from ₹0.21 to ₹0.17 for Q1FY26 to reflect profit after tax rather than total comprehensive income.

Syncom Formulations (India) Limited has fixed September 23, 2026, as the record date for determining shareholder eligibility for a final dividend of ₹0.10 per equity share for the financial year ended March 31, 2026. This payout, representing a 10% distribution on the face value of ₹1 per share, is subject to approval by members at the company’s 38th Annual General Meeting (AGM). The announcement clarifies the timeline for investors seeking to retain or waive their dividend entitlement ahead of the upcoming meeting.

The 38th AGM is scheduled to be held on Wednesday, September 30, 2026, at 2:00 P.M., via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), in compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alongside the dividend approval, shareholders will also vote on the ratification of recent executive appointments, including Rinki Ankit Bankda as Whole-time Director and Rahul Vijay Bankda as Managing Director, following the resignation of previous top management effective August 11, 2026.

Shareholders who wish to voluntarily waive their dividend entitlement, either in full or in part, must submit a duly filled and signed Dividend Waiver Form to the company or its Registrar and Transfer Agent (RTA) on or before September 26, 2026. The form is available on the company’s website and can be submitted via email to finance@sfil.in or to the RTA at investor@ankitonline.com and compliance@ankitonline.com . This deadline ensures the company can process waivers before the dividend payment date.

Governance and Leadership Transition

The Board meeting held on August 11, 2026, concluded with significant changes to the executive team. Shri Kedarmal Shankarlal Bankda (Whole-time Director), Shri Vijay Shankarlal Bankda (Managing Director), and Shri Rahul Vijay Bankda (CFO) resigned from their positions effective August 11, 2026. To address these vacancies, the Board appointed Mrs. Rinki Ankit Bankda as Additional Director and Whole-time Director, and Shri Rahul Vijay Bankda as Additional Director and Managing Director, both effective August 12, 2026. Shri Ankur Vijay Bankda was appointed as the new CFO from the same date. These appointments are pending member approval at the AGM.

Additionally, the Board approved the appointment of Smt. Ruchi Jindal as a Woman Independent Director, effective June 29, 2027, subject to AGM approval. The company also finalized the appointment of a Cost Auditor and an Internal Auditor, with remuneration for the Cost Auditor requiring shareholder ratification. A Scrutinizer was appointed to oversee remote e-voting for the AGM.